Vietnam Journal of Oncology - No. 4/2017, page. 246-249.
Authors: Doan Trung Hiep, Nguyen Ngoc Tue.
Summary: We report a 57-year-old female patient with right colon cancer and liver metastasis that failed 3 previous treatment steps with high-level of microsatellite instability - MSI-H (Microsatellite Instability - High) treated with pembrolizumab 200 mg/cycle, evaluated after 6 months of treatment with complete response to pain due to liver metastasis (VAS from 7 points to 0 point after cycle 3), tumor marker CEA normalized after 1 cycle, CA 19 - 9 normalized after 3 cycles (from 2507 U/ml down to less than 39U/ml) in blood, ECOG PS 2 returned to 0 after 3 cycles, very good partial response of liver metastasis, abdominal lymph nodes completely disappeared. Determining MSI status as a marker for personalized medicine, MSI is not only a marker to help determine the treatment regimen but also helps predict and choose medication from stage II to metastatic stage. Pembrolizumab is one of the salvage therapy for metastatic colorectal cancer that is resistant to 2-3 previous chemotherapy steps.
